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CMR Assessment of Myocarditis
in Patients With Cardiac
Symptoms During H1N1
Viral Infection
Seasonal influenza epidemics are associated with a 2-fold
increase in deaths and mortality, which is especially high in
groups at risk (1). Acute myocarditis during influenza infec-
tion is a well-known complication, and the clinical expression
varies from asymptomatic to fatal congestive cardiac failure (1).
The diagnosis of myocarditis remains a challenge because of
the nonspecific pattern of clinical presentation and the lack of
a standardized diagnostic process. Cardiac magnetic resonance
(CMR) is a widely used tool for diagnosing myocarditis (2).
The aim of our study was to evaluate a population positive for
H1N1 influenza and those with symptoms or signs suggesting
cardiac involvement to be referred for further CMR evalua-
tion.
We screened 200 previously healthy adults age 32 5 years
range 19 to 45 years of age), with nasopharyngeal smears
ositive for H1N1 influenza by polymerase chain reaction
ssay, who presented with symptoms of influenza. Patients
ho had received influenza vaccinations in the past 12 months
nd those with active chronic illness, histories of drug abuse,
acemakers, defibrillators or metallic clips, and/or impaired
enal function were excluded. Thirty-two patients with symp-
oms or signs suggesting cardiac involvement (chest pain,
rrhythmia, shortness of breath, abnormal electrocardio-
raphic [ECG] findings, or abnormal cardiac enzymes) were
eferred for further cardiac evaluation. ECG findings were
bnormal in 16 of 32 patients. All 32 patients were referred for
MR, and their data were compared with those of 32
ge-matched controls. All patients and controls gave written
onsent, and the study was approved by the hospital’s ethics
ommittee.
CMR evaluation was performed within 7 to 14 days after
he onset of symptoms. Repeat CMR was performed 3 months
fter the initial presentation. CMR evidence for myocarditis
as defined according to published criteria as determined from
2-weighted (T2-W) and T1-weighted (T1-W) images be-
ore and after contrast media injection and late gadolinium
nhancement (LGE) images. Results were considered positive
f at least 2 of 3 imaging sequences showed positive results (2).
MR studies were performed using a surface coil in a 1.5-T
ystem. ECG-triggered short inversion time inversion recov-
ry T2-W multislice spin-echo sequences and T1-W mul-
islice spin echo images were also obtained in the axial
rientation with identical parameters before and after an
ntravenous bolus of 0.1 mmol/kg gadolinium diethylenetri- sminepentaacetic acid. Measurements after contrast injection
ere started within 1 min of injection (early T1) in the same
rea as for T2-W imaging. Immediately after the second set of
1-W images was obtained, 0.1 mmol/kg gadolinium dieth-
lenetriamine pentaacetic acid was administered again, and
GE images were taken 15 min later. Images were analyzed
ccording to previously described protocols. For the assess-
ent of left ventricular (LV) function, a steady-state free
recession sequence was used. Images were evaluated by 2
ndependent readers, and the kappa value was 0.85.
Continuous data were expressed as mean  SD. Statistical
nalysis was performed using Mann-Whitney U tests. A p
alue 0.05 was considered to indicate statistical significance.
Thirty-two patients with symptoms or signs suggesting
ardiac involvement were referred for further cardiac evalua-
ion. On admission, 13 patients presented with mild chest
iscomfort and dyspnea, 14 with sinus tachycardia, and 5 with
evere chest pain radiating to both arms. None of the patients
resented with ventricular tachycardia, bundle branch or atrio-
entricular block, or evidence of LV and/or right ventricular
ysfunction. Cardiac enzymes were evaluated in all 32 patients.
Abnormal ECG findings with ST-segment elevation equal
o 1 mm in leads II, III, and aVF were present in only 2 of 5
atients with severe chest pain; both had normal cardiac
nzymes and echocardiographic findings. Cardiac enzymes
ere abnormal in the remaining 3 patients, who had normal
CG and echocardiographic findings (creatine kinase-MB 62
g/ml, 82 ng/ml, and 95 ng/ml [normal values 3.6 ng/ml],
roponin I 6.9 ng/ml, 10.1 ng/ml, and 12.2 ng/ml [normal
alues 0.10 ng/ml]).
The results of CMR were positive for myocarditis in all
atients with severe chest pain, ST-segment elevation, and/or
ncreased cardiac enzymes, as well as in 3 of 14 patients with
inus tachycardia and 2 of 13 with mild chest discomfort and
yspnea (Table 1). In the 10 patients with CMR-documented
yocarditis, the mean LV end-diastolic volume was 124.8 
4.7 ml, the mean LV end-systolic volume was 44.0  1.63
l, and the mean LV ejection fraction was 64.7  1.6%
within normal limits). Wall motion abnormalities were not
dentified in any patient.
In the T2-weighted images, the signal ratio of myocardium
o skeletal muscle was 1.9  0.16 (control value 1.56  0.12,
 0.05), indicative of edema. Focal areas of high T2-signal
ere not identified. In the T1-W images, the early gadolinium
nhancement ratio was 9.22  6.05 (control value 3.08 
.03, p  0.05). LGE areas were identified in all patients
ositive for myocarditis. They were patchy, epimyocardial, or
ndomyocardial, and distributed mainly in the inferior and
ateral walls, although in 2 patients, areas of LGE were also
dentified in the intraventricular septum. Their total extent
as 6.1  4.55%. All patients with abnormal cardiac findings
ere young, with concurrent pneumonia and no histories of
ystemic or coronary artery disease. No correlation between
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Re-evaluation by CMR 3 months later revealed normal findings
n all patients (Fig. 1). Clinical and CMR findings of patients
ositive for myocarditis are presented in Table 1.
The global burden of influenza is believed to be 3 million to 5
illion cases of severe illness and up to 300,000 deaths annually.
lthough myocardial involvement typically is considered a rare
omplication of influenza, the true incidence of myocardial inflam-
ation in influenza, especially in H1N1 influenza, is not well
nown, mainly because of limited accuracy of standard diagnostic
ools.
CMR can easily visualize the entire myocardium, and it is ideal
or a focal process such as myocarditis. The imaging protocol used
n this study captures the 3 basic phenomena of the myocardial
nflammatory response (edema, increased capillary leakage, and
ocal necrosis or fibrosis). A combined CMR approach using T2-W
arly gadolinium enhancement and LGE has sensitivity of 67%,
pecificity of 91%, and diagnostic accuracy of 78% in the detection
f viral myocarditis (2).
The CMR studies in our patients identified the presence of
yocarditis in all patients with severe chest pain, ST-segment
levation, and/or increased myocardial enzyme levels and also in
Table 1. Clinical, ECG, Laboratory and CMR Findings in Patients Positive fo
Patient Symptoms ECG Findings
CK-
(ng/
1 Severe chest pain ST-segment elevation in leads
II, III, and aVF
N
2 Severe chest pain ST-segment elevation in leads
II, III, and aVF
N
3 Severe chest pain N 6
4 Severe chest pain N 8
5 Severe chest pain N 9
6 Chest discomfort/dyspnea N N
7 Chest discomfort/dyspnea N N
8 Sinus tachycardia N N
9 Sinus tachycardia N N
10 Sinus tachycardia N N
CK  creatine kinase; CMR  cardiac magnetic resonance; ECG  electrocardiographic; LG
ventricular ejection fraction; LVESV  left ventricular end-systolic volume; N  normal; Tn 
Figure 1. LGE in a Patient With Myocarditis During H1N1 Infection
Area of late gadolinium enhancement (LGE) in the inferior wall of a patient wit
cardiac magnetic resonance 3 months later (right).ome patients with only sinus tachycardia or chest discomfort
nd/or dyspnea. The LV ejection fraction was preserved, al-
hough the results of CMR examination were positive for the
resence of myocarditis. These findings are in agreement with
hose of previous studies describing the variety of clinical
resentations of myocarditis. Our data also showed that myo-
ardial involvement in H1N1 influenza is frequent and can be
ssessed by CMR, which therefore could be used to rule in or
ule out myocardial involvement in H1N1 influenza, even in the
bsence of other indicators of myocarditis, if myocardial involve-
ent is clinically suspected.
The present study had some limitations: 1) patients presented
ithout evidence of heart failure; 2) biopsies were not clinically
ndicated and thus not performed; 3) children or patients with
evere and/or fulminant forms of H1N1 influenza were not in-
luded; and 4) only short-term follow-up was performed.
According to our findings, in a young, otherwise healthy popula-
ion, myocardial inflammation in H1N1 influenza is frequent but
ppears to be mild. In patients with H1N1 influenza and clinically
uspected myocardial involvement, CMR is a valuable tool to assess for
yocarditis early in the course of H1N1 influenza and during
ollow-up, even in the absence of other clinical markers of myocarditis.
yocarditis on CMR
Tn
(ng/ml) T2 EarlyT1 LGE (%)
LVEDV
(ml)
LVESV
(ml) LVEF (%)
N 1.8 20.2 5 105 40 62
N 2.13 7 4 150 52 65
6.9 1.72 14.65 10 120 42 65
10.1 1.84 6.6 12 118 40 66
12.2 1.92 4.52 15 125 45 64
N 1.8 16.25 4 110 40 64
N 1.7 16.8 2 134 50 63
N 2.1 6.5 3 146 48 67
N 1.62 7.98 2 125 45 64
N 2 2.68 4 115 38 67
late gadolinium enhancement; LVEDV  left ventricular end-diastolic volume; LVEF  left
onin I.
yocarditis during H1N1 infection (left) and disappearance of LGE on follow-upr M
MB
ml)
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Location of Thrombus in
Atrial Fibrillation
We read with great interest the imaging vignette by Gurudevan et
al. (1), presenting 3 patients in whom a thrombus was seen adherent
to the septal left atrium (LA), potentially attributed to a recently
described novel atrial structure, the left atrial septal pouch (LASP).
Krishnan et al. (2) described this new structure and concluded that
LASP has the potential to be a site of stasis with thromboembolic
complications, although Tugcu et al. (3) did not demonstrate
evidence of the association of the presence of LASP with ischemic
stroke or cryptogenic stroke. From these conflicting results, we have
2 comments regarding the underlying pathophysiology and the
clinical implication of LASP.
First, it is really important, in our view, to investigate the effect of
LASP on thromboembolic complications in patients with underlying
cardiovascular disease causing alterations in blood flow. Especially in
patients with rheumatic mitral valve stenosis, with or without atrial
fibrillation, the location of thrombus formation in the left atrium appears
to be different compared to other prothrombotic disease states. In the
presence of atrial fibrillation and rheumatic mitral valve stenosis, in 50%
of the cases, the thrombus is not located in the left atrial appendage
versus 90% of the thrombi found in the appendage in nonvalvular atrial
fibrillation (1).
Second, in patients with mitral valve stenosis, LASP might
potentially be even more prothrombotic, considering: 1) the loca-
tion of thrombus; and 2) the increased risk for atrial fibrillation. This
hypothesis is supported by the increased incidence of thromboembolism
that occurs during transseptal valvuloplasty of the mitral stenosis,
varying from 0.48% to 3.0% (4), compared to the absence of cerebro-
vascular events in case of retrograde mitral valvuloplasty, where there is
no interference with the atrial septum (5). Therefore, the role of LASP in
ischemic stroke or cryptogenic stroke in patients undergoing transseptal
mitral valvuloplasty might be important. On the contrary, retrograde
mitral balloon valvuloplasty in patients with LASP may reduce the
thromboembolic complications. Thus, in patients with mitral valve steno-
sis, the selection of the technique for the optimal outcome might depend
also on the presence of LASP. dThese considerations need to be further investigated. The
mmediate clinical implications after the current observations include the
nvestigation of the presence ofLASP in specific groups, such as rheumatic
itral valve stenosis, because LASP might be an additional criterion for
he choice of treatment. A prospective study is justified with echocardio-
raphic and clinical end points to investigate the accurate prognostic role of
ASP in stroke.
Konstantinos Toutouzas, MD, Andreas Synetos, MD,
Christodoulos Stefanadis, MD*
*First Department of Cardiology, University of Athens, Medical School,
Vas Sofias 114, 11425, Athens, Greece. E-mail: chstefan@med.uoa.gr
doi:10.1016/j.jcmg.2011.01.004
R E F E R E N C E S
1. Gurudevan SV, Shah H, Tolstrup K, Siegel R, Krishnan SC. Septal
thrombus in the left atrium: is the left atrial septal pouch the culprit?
J Am Coll Cardiol Img 2010;3:1284–6.
2. Krishnan SC, Salazar M. Septal pouch in the left atrium: a new
anatomical entity with potential for embolic complications. J Am Coll
Cardiol Intv 2010;3:98–104.
3. Tugcu A, Okajima K, Jin Z, et al. Septal pouch in the left atrium and
risk of ischemic stroke. J Am Coll Cardiol Img 2010;3:1276–83.
4. Liu TJ, Lai HC, Lee WL, et al. Immediate and late outcomes of patients
undergoing transseptal left-sided heart catheterization for symptomatic
valvular and arrhythmic diseases. Am Heart J 2006;151:235–41.
5. Stefanadis CI, Stratos CG, Lambrou SG, et al. Retrograde nontranssep-
tal balloon mitral valvuloplasty: immediate results and intermediate
long-term outcome in 441 cases—a multicenter experience. J Am Coll
Cardiol 1998;32:1009–16.
REPLY
We greatly appreciate the comments and suggestions by Drs.
Toutouzas and colleagues (1) regarding our recent paper on the left
atrial septal pouch (LASP) and thromboembolism (2).
We are pleased that they agree with our proposed mechanism on the
conditions where the LASP is potentially thrombogenic, that is, presence
of sluggish flow of blood arising from the right pulmonary veins (RPV).
According to this hypothesis, RPV blood that flows adjacent to the LASP
in a brisk and laminar fashion plays a protective antithrombotic role
(Figure 5 of our article [2]). Loss of this protective mechanism would be
expected in heart failure or in mitral stenosis (MS) with consequent
thrombogenesis. Our hypothesis may partially explain the increased
incidence of thrombi seen outside the left atrial appendage in rheu-
matic MS. Similarly, sluggish blood flow from the RPV may also play a
role in thrombus formation on septal closure devices, especially with
suboptimally seated devices (creating an “iatrogenic” LASP) (3).We agree
that a prospective study is justified to investigate the thromboembolic
potential of LASP in various disease conditions.
The authors also propose that in patients with MS undergoing
percutaneous valvuloplasty, a retrograde transaortic approach may be
safer than a transseptal approach. They quote a 0.48% to 3.0% incidence
of thromboembolism that occurs during transseptal valvuloplasty
compared to the absence of strokes with a transaortic approach (4,5).
hey raise the intriguing possibility that some of the strokes seen with
he transatrial valvuloplasty approach may have been due to the
islodgment of a thrombus adherent to a LASP. However, in the
